A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs Siponimod (Primary)
- Indications Polymyositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 07 Oct 2016 Status changed from recruiting to discontinued.
- 01 Sep 2016 This trial is prematurely ended in Czech Republic (18 May 2016).
- 20 Aug 2016 This trial is prematurely ended in Poland.